According to FutureWise analysis the market for antibody drug conjugate in 2023 was US$ 10.50 billion, and is expected to reach US$ around 26.68 billion by 2031 at a CAGR of 16.6%. Antibody-drug conjugates (ADCs) mark a significant breakthrough in the realm of targeted biopharmaceutical therapies. These innovative therapeutics combine monoclonal antibodies, which selectively identify surface...

According to FutureWise analysis, the market for Antibody Drug Conjugate is expected to reach US$ 26.68 billion by 2031 at a CAGR of 16.6% over the forecast period of 2023-2031. Antibody-drug conjugates (ADCs) are specialized biopharmaceutical medications that combine monoclonal antibodies, which specifically recognize surface antigens on tumor cells, with powerful anti-cancer agents connected...